Can Geron Turn It Around?


Today, health-care analysts David Williamson and Brenton Flynn look at the biggest news across their sector.

One big headline is Geron's performance in August, when the company had weak results for one of its lead cancer drugs. While David doesn't think it spells doom for the company, it removes a big safety net for the company that investors could have previously counted on as a fall-back.

When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

The article Can Geron Turn It Around? originally appeared on

Brenton Flynn, Dave Williamson, and The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published